

Special Issue

Cancer Vaccines and Immunotherapies

Message from the Guest Editor

This Special Issue aims to highlight cutting-edge research in the rapidly evolving field of cancer vaccines and immunotherapy, with a particular focus on novel vaccine strategies and immune-based treatments. We welcome original research, review articles, and perspective manuscripts that explore advancements in cancer vaccine development, immune modulation, and novel therapeutic approaches. Topics of interest include, but are not limited to, **mRNA cancer vaccines, combination immunotherapies (checkpoint inhibitors, cytokine therapies, and immune adjuvants), dendritic cell-based vaccines, tumor-derived exosome vaccines, and neoantigen-based personalized cancer vaccines**. Additionally, we encourage submissions related to tumor microenvironment modulation for vaccine efficacy, CAR-T and TCR-T cell therapies, novel adjuvants and delivery systems, and biomarker-driven predictive models for vaccine response. Emerging areas such as **AI-driven vaccine design, multi-omics approaches in tumor immunology, microbiome interactions with cancer immunotherapy, and epigenetic modulation of immune responses** are also highly relevant to this Special Issue.

Guest Editor

Prof. Dr. Subbaya Subramanian
Department of Surgery, University of Minnesota, Minneapolis, MN
55455, USA

Deadline for manuscript submissions

30 September 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/237555

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).